Updates are available Correction dated 2023-02-17
Click to view Correction: https://doi.org/10.1038/s41569-023-00848-4
-
Authors
Sud, Karan
Narula, Navneet http://orcid.org/0000-0002-6832-3645
Aikawa, Elena http://orcid.org/0000-0001-7835-2135
Arbustini, Eloisa
Pibarot, Philippe http://orcid.org/0000-0002-3607-279X
Merlini, Giampaolo http://orcid.org/0000-0001-7680-3254
Rosenson, Robert S.
Seshan, Surya V.
Argulian, Edgar
Ahmadi, Amir
Zhou, Fang http://orcid.org/0000-0002-5542-2994
Moreira, Andre L.
Côté, Nancy
Tsimikas, Sotirios
Fuster, Valentin
Gandy, Sam
Bonow, Robert O.
Gursky, Olga
Narula, Jagat
- License Information
-
More Information
Article History
Accepted: 17 November 2022
First Online: 9 January 2023
Change Date: 17 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41569-023-00848-4
Competing interests
: P.P. has received grant funding from Cardiac Phoenix, Edwards Lifesciences, Medtronic and Pi-Cardia for echocardiography core laboratory analyses and research studies in the field of transcatheter valve therapies, for which he received no personal compensation; he has also received lecture fees from Edwards Lifesciences and Medtronic. R.S.R. has received research grants to his institution from Amgen, Arrowhead, NIH, Novartis and Regeneron, is a member of the advisory board of Amgen, Novartis, Regeneron and 89 Bio, has received honoraria for non-promotional speaking from Kowa, has stock holdings with MediMergent, and receives royalties from Wolters Kluwer (UpToDate). S.T. is a co-inventor who receives royalties from patents owned by University of California, San Diego on oxidation-specific antibodies and biomarkers related to oxidized lipoproteins, and is a co-founder who has equity interests in Kleanthi Diagnostics and in Oxitope and affiliates. Although these relationships have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to Kleanthi and Oxitope, the research findings included in this particular publication do not necessarily relate to the interests of Kleanthi and Oxitope. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with conflict of interest policies. S.G. serves as a consultant for Altpep, Cognition Therapeutics, and Ritrova Therapeutics and is a founder of Recuerdo Pharmaceuticals (inactive), has served as a consultant in the past for Diagenic, has received research support in the past from Avid, Baxter, Pfizer and Warner-Lambert, and also receives compensation for chart review in connection with medical litigation in the area of cognitive function. The other authors declare no competing interests.
